Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.

The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acute Myeloid Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Freiburg Mdical Center

Freiburg im Breisgau, 79106, Germany

Location status: Recruiting

Location contact

ECTU

CONTACT

[email protected]

+4976127034020

About this study

The study will investigate biomarkers including humen endogenous retrovirus expression and T cell phenotypic analysis in patients with AML with NPM1 mutations or KMT2A rearrangements. These biomarkers have been previously described: Blood. 2026 Jan 29;147(5):584-601. doi: 10.1182/blood.2025029712. PMID: 41144759

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements
Hematological relapse after allo-HCT
18 years or older

Exclusion criteria

no signed informed consent

Treatment and study plan

Primary outcomes

Correlative biomarker

Time frame: 1 year

HERV expression by AML cells
Biomarkers will be correlated with survival and leukemia response

Time frame: may 2026 till may 2027

The biomarkers HERV, HLA class I and II, T cell phenotype

Study contacts

Contact information is provided by the study sponsor or research team.

Robert Zeiser, MD

CONTACT

[email protected]

+4976127034020

Sponsors and collaborators

Lead sponsor

University of Freiburg

Other

Registry information

Acronym: AML_MenALLO

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Jun 4, 2026
Registry last updated: Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting